NEUROGENE INC (NGNE)
(Delayed Data from NSDQ)
$48.59 USD
+4.18 (9.41%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $48.35 -0.24 (-0.49%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NGNE 48.59 +4.18(9.41%)
Will NGNE be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NGNE based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for NGNE
Commit To Purchase Neurogene At $25, Earn 16% Using Options
Video: Wednesday's ETF Movers: DWAS, LIT
BlackRock Health Sciences Term Trust Q2 2024 Commentary
Three new option listings and one option delisting on August 14th
Buy Rating for Neurogene: Promising Rett Syndrome Program and Strong Financial Outlook